KLK3 and neoplasm: The number of treatment cycles was determined based on PSA changes, molecular tumor burden response via post-therapeutic single photon emission computed tomography (SPECT)/CT imaging (StarGuideTM, GE HealthCare, Chicago, Illinois, USA), and evaluations of hematologic and chemistry parameters, as well as overall quality of life.